Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma.

The goal of this study was to evaluate the anti-tumour activity and toxicoses of vinorelbine as a palliative rescue therapy for dogs with primary urinary bladder carcinoma. Thirteen dogs refractory to prior chemotherapeutics and one dog naïve to chemotherapeutic treatment were enrolled. Vinorelbine (15 mg m(-2) IV) was administered intravenously along with concurrent oral anti-inflammatory drugs, if tolerated. A median of six doses of vinorelbine (range: 1-16) was administered. Two dogs (14%) had partial responses, and eight (57%) experienced stable disease. Subjective improvement in clinical signs was noted in 11 dogs (78%). Adverse events were mild and primarily haematological in nature. Median time to progression was 93 days (range: 20-239 days). Median survival time for all dogs was 187 days; median survival for 13 pre-treated dogs was 207 days. Vinorelbine may have utility in the management of canine primary urinary bladder carcinoma and should be evaluated in a prospective study.

Results of a surveillance program for persons living around the Nevada Test Site--1971 to 1980.

A continuing program has been conducted since 1970 to determine levels of radioactive nuclides in adults and children from families residing in communities and ranches surrounding the Nevada Test Site. Twice each year these persons receive a whole-body count and physical examination; a urine sample from each is also submitted for radionuclide analyses. The only fission-product radionuclide routinely found in whole-body counting has been 137Cs at concentrations similar to those in persons living in other areas of the United States. The physical examinations reveal a generally healthy population, and urine samples have shown no remarkable radionuclide content.